ArticleThe Prostate2016

Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide.

Mark C Markowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.